跳至主要内容
临床试验/NCT00935688
NCT00935688已完成4 期

An Examination of ACT Strategy in South-central Asia on Falciparum Malaria in a Context Where Vivax is the Major Species

London School of Hygiene and Tropical Medicine2 个研究点 分布在 1 个国家目标入组 4,200 人开始时间: 2009年5月最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
4,200
试验地点
2
主要终点
Proportion of patients correctly treated

研究概览

简要总结

In areas of which are co-endemic for vivax and falciparum malaria, treatments for the two diseases often differ and this may lead to mistreatment. This places an emphasis on diagnosis at the health service provision level. Diagnosis is also important when malaris endemicity is low - most fevers are not caused by disease. These two issues mean that most malaria and fevers are not adequately treated, even though the drugs may be effective; many patients who do not have malaria are treated for the disease, and patients with malaria may get the wrong treatment for their species. The study aims to test the effectiveness of employing rapid diagnostic tests and will study the effect on correct treatment.

详细描述

The study will randomly assign diagnostic methods, either with clinical diagnosis, field microscopy or rapid diagnostic tests. The study will take place in 22 clinics in Eastern and Northern Afghanistan, both areas with low transmission of predominantly vivax malaria. They differ in their locations and their current standard diagnostic methods.

The study will examine the result of the diagnostic test in the clinic against the result of reference slides and PCR to estimate the number of cases correctly treated in each arm. This will be a measure of the effectiveness of diagnosis (and the physicians response to the diagnosis) and be influential in considering modalities for diagnostic delivery

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
Single (Outcomes Assessor)

入排标准

性别
All
接受健康志愿者

入选标准

  • Any patient where the clinician* considers malaria in the diagnosis - either prescribing an antimalarial or would request a malaria test if available or referring for diagnosis of malaria elsewhere.
  • Patient, or parent/guardian, gives informed consent to the study.

排除标准

  • Patients with a result from another facility
  • Patients referred on for diagnosis in the private sector
  • Patients the clinician decides to treat presumptively without requesting a test (defined as treating prior to randomisation)
  • Where the clinician requests microscopy specifically due to clinical need prior to randomisation will not be randomised in the trial, but will be noted as part of the study and a reference slide and clinical information will be taken following consent.

结局指标

主要结局

Proportion of patients correctly treated

时间窗: 2009-2010

Composite measure defined as patients with Pf malaria receiving ACT Drugs; Pv malaria receiving CQ; patients with no malaria receiving no antimalarial drugs. NOTE: Previously reported here as "Proportion of patients incorrectly treated" being 1 minus the Proportion correctly treated. No change in how the outcome was measured.

次要结局

  • % of PV patients not receiving CQ % of PF patients not receiving SP/AS(2009-2010)
  • Diagnostic Accuracy of the different malaria tests(2009-2010)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mark Rowland

Principle Investigator, Professor of Entomology and Malaria Control

London School of Hygiene and Tropical Medicine

研究点 (2)

Loading locations...

相似试验

Examination of ACT Implementation in a Vivax /... | 临床试验